Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
35
BBIO Quote, Financials, Valuation and Earnings
Last price:
$68.14
Seasonality move
:
-7.53%
Day range:
$67.42 - $70.85
52-week range:
$28.33 - $84.94
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
36.69x
P/B ratio:
--
Volume:
5.1M
Avg. volume:
3.4M
1-year change:
85.14%
Market cap:
$13.1B
Revenue:
$221.9M
EPS (TTM):
-$4.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BBIO
BridgeBio Pharma, Inc.
|
$149.1M | -$0.62 | 51.06% | -36.97% | $98.38 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
COGT
Cogent Biosciences, Inc.
|
-- | -$0.51 | -- | -4.68% | $53.83 |
|
INSM
Insmed, Inc.
|
$264M | -$1.17 | 225.21% | -34.8% | $212.95 |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$141.8M | $0.06 | 33.77% | -95% | $116.09 |
|
SRPT
Sarepta Therapeutics, Inc.
|
$391M | -$0.77 | -49.33% | -91.57% | $21.43 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BBIO
BridgeBio Pharma, Inc.
|
$68.14 | $98.38 | $13.1B | -- | $0.00 | 0% | 36.69x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$336.19 | $457.00 | $44.6B | 148.95x | $0.00 | 0% | 12.08x |
|
COGT
Cogent Biosciences, Inc.
|
$37.34 | $53.83 | $5.7B | -- | $0.00 | 0% | 55.99x |
|
INSM
Insmed, Inc.
|
$164.91 | $212.95 | $35.2B | -- | $0.00 | 0% | 54.09x |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$105.16 | $116.09 | $5.4B | -- | $0.00 | 0% | 11.35x |
|
SRPT
Sarepta Therapeutics, Inc.
|
$18.88 | $21.43 | $2B | 20.50x | $0.00 | 0% | 0.81x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BBIO
BridgeBio Pharma, Inc.
|
350.59% | 0.352 | 27% | 3.52x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
COGT
Cogent Biosciences, Inc.
|
27.29% | 3.084 | 4.31% | 14.08x |
|
INSM
Insmed, Inc.
|
50.57% | 2.488 | 2.04% | 3.35x |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
52.19% | 1.284 | 8.47% | 3.01x |
|
SRPT
Sarepta Therapeutics, Inc.
|
48.64% | -0.463 | 61.92% | 1.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BBIO
BridgeBio Pharma, Inc.
|
$113.4M | -$136.4M | -109.98% | -- | -112.97% | -$112.4M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
COGT
Cogent Biosciences, Inc.
|
-$1.2M | -$99.5M | -83.75% | -104.81% | -- | -$79.9M |
|
INSM
Insmed, Inc.
|
$217.7M | -$249.7M | -77.98% | -192.35% | -94.64% | -$294.2M |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$107.4M | $2.6M | -7.32% | -16.73% | 1.96% | $39.5M |
|
SRPT
Sarepta Therapeutics, Inc.
|
$230.1M | -$62.9M | -10.24% | -20.67% | -15.75% | -$55.6M |
BridgeBio Pharma, Inc. vs. Competitors
-
Which has Higher Returns BBIO or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -153.22% compared to BridgeBio Pharma, Inc.'s net margin of 16.99%. BridgeBio Pharma, Inc.'s return on equity of -- beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital BBIOBridgeBio Pharma, Inc.93.98% -$0.95 $781.7M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About BBIO or ALNY?
BridgeBio Pharma, Inc. has a consensus price target of $98.38, signalling upside risk potential of 44.38%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 35.94%. Given that BridgeBio Pharma, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe BridgeBio Pharma, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BBIOBridgeBio Pharma, Inc.15 1 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is BBIO or ALNY More Risky?
BridgeBio Pharma, Inc. has a beta of 1.128, which suggesting that the stock is 12.752% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock BBIO or ALNY?
BridgeBio Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBIO or ALNY?
BridgeBio Pharma, Inc. quarterly revenues are $120.7M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. BridgeBio Pharma, Inc.'s net income of -$184.9M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, BridgeBio Pharma, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 148.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma, Inc. is 36.69x versus 12.08x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBIOBridgeBio Pharma, Inc.36.69x -- $120.7M -$184.9M ALNYAlnylam Pharmaceuticals, Inc.12.08x 148.95x $1.1B $186.4M
-
Which has Higher Returns BBIO or COGT?
Cogent Biosciences, Inc. has a net margin of -153.22% compared to BridgeBio Pharma, Inc.'s net margin of --. BridgeBio Pharma, Inc.'s return on equity of -- beat Cogent Biosciences, Inc.'s return on equity of -104.81%.
Company Gross Margin Earnings Per Share Invested Capital BBIOBridgeBio Pharma, Inc.93.98% -$0.95 $781.7M COGTCogent Biosciences, Inc.-- -$0.69 $875.2M -
What do Analysts Say About BBIO or COGT?
BridgeBio Pharma, Inc. has a consensus price target of $98.38, signalling upside risk potential of 44.38%. On the other hand Cogent Biosciences, Inc. has an analysts' consensus of $53.83 which suggests that it could grow by 44.17%. Given that BridgeBio Pharma, Inc. has higher upside potential than Cogent Biosciences, Inc., analysts believe BridgeBio Pharma, Inc. is more attractive than Cogent Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BBIOBridgeBio Pharma, Inc.15 1 0 COGTCogent Biosciences, Inc.9 2 0 -
Is BBIO or COGT More Risky?
BridgeBio Pharma, Inc. has a beta of 1.128, which suggesting that the stock is 12.752% more volatile than S&P 500. In comparison Cogent Biosciences, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.923%.
-
Which is a Better Dividend Stock BBIO or COGT?
BridgeBio Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma, Inc. pays -- of its earnings as a dividend. Cogent Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBIO or COGT?
BridgeBio Pharma, Inc. quarterly revenues are $120.7M, which are larger than Cogent Biosciences, Inc. quarterly revenues of --. BridgeBio Pharma, Inc.'s net income of -$184.9M is lower than Cogent Biosciences, Inc.'s net income of -$102.5M. Notably, BridgeBio Pharma, Inc.'s price-to-earnings ratio is -- while Cogent Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma, Inc. is 36.69x versus 55.99x for Cogent Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBIOBridgeBio Pharma, Inc.36.69x -- $120.7M -$184.9M COGTCogent Biosciences, Inc.55.99x -- -- -$102.5M
-
Which has Higher Returns BBIO or INSM?
Insmed, Inc. has a net margin of -153.22% compared to BridgeBio Pharma, Inc.'s net margin of -124.5%. BridgeBio Pharma, Inc.'s return on equity of -- beat Insmed, Inc.'s return on equity of -192.35%.
Company Gross Margin Earnings Per Share Invested Capital BBIOBridgeBio Pharma, Inc.93.98% -$0.95 $781.7M INSMInsmed, Inc.82.51% -$1.54 $1.5B -
What do Analysts Say About BBIO or INSM?
BridgeBio Pharma, Inc. has a consensus price target of $98.38, signalling upside risk potential of 44.38%. On the other hand Insmed, Inc. has an analysts' consensus of $212.95 which suggests that it could grow by 29.13%. Given that BridgeBio Pharma, Inc. has higher upside potential than Insmed, Inc., analysts believe BridgeBio Pharma, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BBIOBridgeBio Pharma, Inc.15 1 0 INSMInsmed, Inc.17 1 0 -
Is BBIO or INSM More Risky?
BridgeBio Pharma, Inc. has a beta of 1.128, which suggesting that the stock is 12.752% more volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.105, suggesting its more volatile than the S&P 500 by 10.538%.
-
Which is a Better Dividend Stock BBIO or INSM?
BridgeBio Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBIO or INSM?
BridgeBio Pharma, Inc. quarterly revenues are $120.7M, which are smaller than Insmed, Inc. quarterly revenues of $263.8M. BridgeBio Pharma, Inc.'s net income of -$184.9M is higher than Insmed, Inc.'s net income of -$328.5M. Notably, BridgeBio Pharma, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma, Inc. is 36.69x versus 54.09x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBIOBridgeBio Pharma, Inc.36.69x -- $120.7M -$184.9M INSMInsmed, Inc.54.09x -- $263.8M -$328.5M
-
Which has Higher Returns BBIO or MIRM?
Mirum Pharmaceuticals, Inc. has a net margin of -153.22% compared to BridgeBio Pharma, Inc.'s net margin of 2.18%. BridgeBio Pharma, Inc.'s return on equity of -- beat Mirum Pharmaceuticals, Inc.'s return on equity of -16.73%.
Company Gross Margin Earnings Per Share Invested Capital BBIOBridgeBio Pharma, Inc.93.98% -$0.95 $781.7M MIRMMirum Pharmaceuticals, Inc.80.75% $0.05 $610.8M -
What do Analysts Say About BBIO or MIRM?
BridgeBio Pharma, Inc. has a consensus price target of $98.38, signalling upside risk potential of 44.38%. On the other hand Mirum Pharmaceuticals, Inc. has an analysts' consensus of $116.09 which suggests that it could grow by 10.4%. Given that BridgeBio Pharma, Inc. has higher upside potential than Mirum Pharmaceuticals, Inc., analysts believe BridgeBio Pharma, Inc. is more attractive than Mirum Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BBIOBridgeBio Pharma, Inc.15 1 0 MIRMMirum Pharmaceuticals, Inc.8 0 0 -
Is BBIO or MIRM More Risky?
BridgeBio Pharma, Inc. has a beta of 1.128, which suggesting that the stock is 12.752% more volatile than S&P 500. In comparison Mirum Pharmaceuticals, Inc. has a beta of 0.492, suggesting its less volatile than the S&P 500 by 50.821%.
-
Which is a Better Dividend Stock BBIO or MIRM?
BridgeBio Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mirum Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma, Inc. pays -- of its earnings as a dividend. Mirum Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBIO or MIRM?
BridgeBio Pharma, Inc. quarterly revenues are $120.7M, which are smaller than Mirum Pharmaceuticals, Inc. quarterly revenues of $133M. BridgeBio Pharma, Inc.'s net income of -$184.9M is lower than Mirum Pharmaceuticals, Inc.'s net income of $2.9M. Notably, BridgeBio Pharma, Inc.'s price-to-earnings ratio is -- while Mirum Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma, Inc. is 36.69x versus 11.35x for Mirum Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBIOBridgeBio Pharma, Inc.36.69x -- $120.7M -$184.9M MIRMMirum Pharmaceuticals, Inc.11.35x -- $133M $2.9M
-
Which has Higher Returns BBIO or SRPT?
Sarepta Therapeutics, Inc. has a net margin of -153.22% compared to BridgeBio Pharma, Inc.'s net margin of -45.06%. BridgeBio Pharma, Inc.'s return on equity of -- beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.
Company Gross Margin Earnings Per Share Invested Capital BBIOBridgeBio Pharma, Inc.93.98% -$0.95 $781.7M SRPTSarepta Therapeutics, Inc.57.63% -$1.80 $2.6B -
What do Analysts Say About BBIO or SRPT?
BridgeBio Pharma, Inc. has a consensus price target of $98.38, signalling upside risk potential of 44.38%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $21.43 which suggests that it could grow by 13.53%. Given that BridgeBio Pharma, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe BridgeBio Pharma, Inc. is more attractive than Sarepta Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BBIOBridgeBio Pharma, Inc.15 1 0 SRPTSarepta Therapeutics, Inc.7 14 3 -
Is BBIO or SRPT More Risky?
BridgeBio Pharma, Inc. has a beta of 1.128, which suggesting that the stock is 12.752% more volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.731%.
-
Which is a Better Dividend Stock BBIO or SRPT?
BridgeBio Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BridgeBio Pharma, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBIO or SRPT?
BridgeBio Pharma, Inc. quarterly revenues are $120.7M, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. BridgeBio Pharma, Inc.'s net income of -$184.9M is lower than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, BridgeBio Pharma, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BridgeBio Pharma, Inc. is 36.69x versus 0.81x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBIOBridgeBio Pharma, Inc.36.69x -- $120.7M -$184.9M SRPTSarepta Therapeutics, Inc.0.81x 20.50x $399.4M -$179.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
